Hydroxychloroquine (HCQ) decreases the benefit of anti-PD-1 immune checkpoint blockade in tumor immunotherapy. Krueger J, Santinon F, Kazanova A, Issa ME, et al. PLoS One 2021;16:e0251731.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Krueger J, Santinon F, Kazanova A, Issa ME, et al. Hydroxychloroquine (HCQ) decreases the benefit of anti-PD-1 immune checkpoint blockade in tumor immunotherapy. PLoS One 2021;16:e0251731.
PMID: 34181666